Rapamycin in aging and disease: maximizing efficacy while minimizing side effects
Metrics: PDF 2248 views | HTML 2409 views | ?
Simon C. Johnson1 and Matt Kaeberlein2
1 Department of Genetics, Albert Einstein Medical College, New York, NY, USA
2 Department of Pathology, University of Washington, Seattle, WA, USA
Matt Kaeberlein, email:
Keywords: mTOR, target of rapamycin, healthspan, mitochondria, mitochondria disease
Received: April 22, 2016 Accepted: June 16, 2016 Published: July 01, 2016
Experimental geroscience has identified rapamycin as a top candidate for promoting healthy aging and longevity in mammals. As multiple independent studies have successfully reproduced the lifespan and healthspan promoting effects of rapamycin, the focus has shifted to possible translational use. While a promising compound, clinical use of rapamycin is limited by concerns of side effects associated with the drug. Studies aimed at defining optimal dosage regimen, delivery route, and formulation will allow for benefits to be maximized while reducing side effects.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.